Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Hormone receptor-positive breast cancer (HR+ BC) is known to be relatively insensitive to chemotherapy, and since chemotherapy has remained the major neoadjuvant therapy for HR+ BC, the undetermined mechanism of chemoresistance and how chemotherapy reshapes the immune microenvironment need to be explored by high-throughput technology. By using single-cell RNA sequencing and multiplexed immunofluorescence staining analysis of HR+ BC samples (paired pre- and post-neoadjuvant chemotherapy (NAC)), the levels of previously unrecognized immune cell subsets, including CD8+ T cells with pronounced expression of T-cell development (LMNA) and cytotoxicity (FGFBP2) markers, CD4+ T cells characterized by proliferation marker (ATP1B3) expression and macrophages characterized by CD52 expression, were found to be increased post-NAC, which were predictive of chemosensitivity and their antitumor function was also validated with in vitro experiments. In terms of immune checkpoint expression of CD8+ T cells, we found their changes were inconsistent post-NAC, that LAG3, VSIR were decreased, and PDCD1, HAVCR2, CTLA4, KLRC1 and BTLA were increased. In addition, we have identified novel genomic and transcriptional patterns of chemoresistant cancer cells, both innate and acquired, and have confirmed their prognostic value with TCGA cohorts. By shedding light on the ecosystem of HR+ BC reshaped by chemotherapy, our results uncover valuable candidates for predicting chemosensitivity and overcoming chemoresistance in HR+ BC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:585 |
|---|---|
| Enthalten in: |
Cancer letters - 585(2024) vom: 31. März, Seite 216656 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jia, Fang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ATP1B3 protein, human |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2024.216656 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367572362 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367572362 | ||
| 003 | DE-627 | ||
| 005 | 20240305232236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2024.216656 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM367572362 | ||
| 035 | |a (NLM)38266804 | ||
| 035 | |a (PII)S0304-3835(24)00050-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jia, Fang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Hormone receptor-positive breast cancer (HR+ BC) is known to be relatively insensitive to chemotherapy, and since chemotherapy has remained the major neoadjuvant therapy for HR+ BC, the undetermined mechanism of chemoresistance and how chemotherapy reshapes the immune microenvironment need to be explored by high-throughput technology. By using single-cell RNA sequencing and multiplexed immunofluorescence staining analysis of HR+ BC samples (paired pre- and post-neoadjuvant chemotherapy (NAC)), the levels of previously unrecognized immune cell subsets, including CD8+ T cells with pronounced expression of T-cell development (LMNA) and cytotoxicity (FGFBP2) markers, CD4+ T cells characterized by proliferation marker (ATP1B3) expression and macrophages characterized by CD52 expression, were found to be increased post-NAC, which were predictive of chemosensitivity and their antitumor function was also validated with in vitro experiments. In terms of immune checkpoint expression of CD8+ T cells, we found their changes were inconsistent post-NAC, that LAG3, VSIR were decreased, and PDCD1, HAVCR2, CTLA4, KLRC1 and BTLA were increased. In addition, we have identified novel genomic and transcriptional patterns of chemoresistant cancer cells, both innate and acquired, and have confirmed their prognostic value with TCGA cohorts. By shedding light on the ecosystem of HR+ BC reshaped by chemotherapy, our results uncover valuable candidates for predicting chemosensitivity and overcoming chemoresistance in HR+ BC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chemotherapy resistance | |
| 650 | 4 | |a HR(+) breast cancer | |
| 650 | 4 | |a Neoadjuvant chemotherapy | |
| 650 | 4 | |a Single cell sequencing | |
| 650 | 4 | |a Tumor microenvironment | |
| 650 | 7 | |a ATP1B3 protein, human |2 NLM | |
| 650 | 7 | |a Sodium-Potassium-Exchanging ATPase |2 NLM | |
| 650 | 7 | |a EC 7.2.2.13 |2 NLM | |
| 700 | 1 | |a Sun, Shanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaxin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wenwen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Huanhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Xiaoxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wuzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lesang |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Siwei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hailong |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Wenjie |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Hongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiuyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Chao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 585(2024) vom: 31. März, Seite 216656 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:585 |g year:2024 |g day:31 |g month:03 |g pages:216656 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216656 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 585 |j 2024 |b 31 |c 03 |h 216656 | ||